Treatment (VCBA) for Urinary Bladder Cancer
Phase-Based Progress Estimates
Effectiveness
Safety
USC / Norris Comprehensive Cancer Center, Los Angeles, CA
Urinary Bladder Cancer+3 More
Quality-of-Life Assessment - OtherEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This early phase I trial tests the feasibility, functionality, and sustainability of robotic vascularized composite bladder allograft transplantation in treating patients with bladder cancer. A vascularized bladder allograft transplantation may provide a more durable and better tolerated alternative to urinary diversion using bowel in patients with bladder cancer.
Eligible Conditions
- Urinary Bladder Cancer
- Muscle Invasive Bladder Carcinoma
- Stage II Bladder Cancer AJCC v8
- Stage IIIA Bladder Cancer AJCC v8
Treatment Effectiveness
Effectiveness Progress
Other trials for Urinary Bladder Cancer
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: At 7, 30, and 90 days
Day 90
Bladder function
At completion of transplantation procedure
Technical success of vascularized composite bladder allograft (VCBA) transplantation
Day 90
Adverse events associated with VCBA transplantation
Year 1
Acute transplant rejection
Delayed transplant rejection
Trial Safety
Safety Progress
Other trials for Urinary Bladder Cancer
Trial Design
1 Treatment Group
Treatment (VCBA)
1 of 1
Experimental Treatment
5 Total Participants · 1 Treatment Group
Primary Treatment: Treatment (VCBA) · No Placebo Group · N/A
Treatment (VCBA)Experimental Group · 2 Interventions: Quality-of-Life Assessment, Vascularized Autograft · Intervention Types: Other, Procedure
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at 7, 30, and 90 days
Closest Location: USC / Norris Comprehensive Cancer Center · Los Angeles, CA
2010First Recorded Clinical Trial
0 TrialsResearching Urinary Bladder Cancer
126 CompletedClinical Trials
Eligibility Criteria
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have bladder cancer that is localized, non-metastatic, muscle-invasive (cT2 or T3) requiring radical cystectomy.
Patients that are on immunosuppression for pre-existing solid organ transplantation will be included in this study.
Patients must demonstrate appropriate manual dexterity or sufficient assistance at home to perform clean intermittent catheterizations as needed
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments